Galectin‐4 serves as a prognostic biomarker for the early recurrence / metastasis of hepatocellular carcinoma

Cai, Zhixiong; Zeng, Yongyi; Xu, Beibei; Gao, Yunzhen; Wang, Sen; Zeng, Jinhua; Chen, Lihong; Huang, Aimin; Liu, Xiaolong; Liu, Jingfeng

doi:10.1111/cas.12536

Cited by 53 publications

(51 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ÃÃÃ , P < 0.001 by unpaired Student t test. (12,13). Despite the disagreement across cancer types, we identified galectin-4 as a major driver gene governing prostate cancer metastasis in a murine model.…”

Section: Introductionmentioning

confidence: 90%

Metastatic Progression of Prostate Cancer Is Mediated by Autonomous Binding of Galectin-4-O-Glycan to Cancer Cells

et al. 2016

View full text Add to dashboard Cite

Metastatic prostate cancer continues to pose a difficult therapeutic challenge. Prostate cancer progression is associated with aberrant O-glycosylation of cancer cell surface receptors, but the functional impact of such events is uncertain. Here we report spontaneous metastasis of human prostate cancer xenografts that express high levels of galectin-4 along with genetic signatures of EGFR-HER2 signaling and O-glycosylation. Galectin-4 expression in clinical specimens of prostate cancer correlated with poor patient survival. Galectin-4 binding to multiple receptor tyrosine kinases stimulated their autophosphorylation, activated expression of pERK, pAkt, fibronectin, and Twist1, and lowered expression of E-cadherin, thereby facilitating epithelial-mesenchymal transition, invasion, and metastasis. In vivo investigations established that galectin-4 expression enabled prostate cancer cells to repopulate tumors in orthotopic and heterotopic tissues. Notably, these effects of galectin-4 relied upon O-glycosylation mediated by C1GALT1, a galactosyltransferase implicated in other cancers. Parallel changes in galectin-4 and O-glycosylation triggered aberrant receptor signaling and more aggressive invasive character in prostate cancer cells, which through better survival in the circulation also contributed to the bulk cell progeny of distal tumors. Our findings establish galectin-4 and C1GALT1-mediated glycosylation in a signaling axis that is activated during prostate cancer progression, with implications for therapeutic targeting of advanced metastatic disease. Cancer Res; 76(19); 5756-67. ©2016 AACR.

show abstract

Section: Introductionmentioning

confidence: 90%

Metastatic Progression of Prostate Cancer Is Mediated by Autonomous Binding of Galectin-4-O-Glycan to Cancer Cells

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Galectin 4 has been regarded as a differentiation biomarker in colon cancer [21]. The loss of galectin 4 expression is also linked to increased tumor size and tumor differentiation in hepatocellular carcinoma and lung cancer [12,22]. Most patients received adjuvant chemotherapy in the present study.…”

Section: Discussionmentioning

confidence: 81%

Galectin 4 is a biomarker for early recurrence and death after surgical resection for pancreatic ductal adenocarcinoma

Ansari

Zhou

et al. 2019

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

Background: Galectins are a group of carbohydrate-binding proteins that are involved in neoplastic development and progression. In a previous mass spectrometry-based study, we identified galectin 4 as a down-regulated protein in short-term survivors of pancreatic cancer. This study was performed to validate the prognostic value of galectin 4 in a larger cohort of pancreatic cancer patients undergoing surgical resection. Methods: Galectin 4 expression was evaluated by tissue microarrays and immunohistochemistry in 140 patients with surgically resected pancreatic cancer. Kaplan-Meier and Cox proportional hazards modeling were used to explore the association between galectin 4 and survival. Results: Galectin 4 staining expression was positive in 111 cases (79.3%). The expression of galectin 4 was significantly associated with tumor size (p ¼ .008) and differentiation (p ¼ .001). Galectin 4 expression was significantly correlated with disease recurrence within 1 year of surgery (adjusted HR 0.485, p ¼ .027). There was also a significant association between galectin 4 and overall survival at 1 year (adjusted HR 0.482, p ¼ .047) and at 3 years (adjusted HR 0.550, p ¼ .025). Conclusion: Galectin 4 expression is a novel biomarker for early recurrence and mortality after surgical resection for pancreatic cancer.

show abstract

“…Galectin-4, a multifunctional lectin present intra-and extra-cellularly, has recently been identified as a potential prognostic marker in HCC [65] . Another avenue of potential research is the application of mathematical modeling techniques using 18 F-FLT-PET to enhance the visualization of liver lesions [66].…”

Section: Conclusion and Future Perspectivementioning

confidence: 99%

The emerging role of positron emission tomography in hepatocellular carcinoma

2015

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide. HCC a heterogeneous disease occurring on the background of cirrhosis. The presence of cirrhosis limits the sensitivity of conventional imaging modalities in differentiating HCC from surrounding cirrhotic parenchyma. Positron emission tomography (PET) using F-fluorodeoxyglucose (F-FDG) is widely used for assessing a variety of malignancies, however, has poor sensitivity in the evaluation of HCC. This has led to the investigation of other radiotracers such as C-acetate andC-choline, with improved sensitivity in terms of detection and therapeutic response. In this review, we discuss the emerging field of PET imaging for the detection, staging and assessment of treatment response in HCC. In particular we discuss the role of F-FDG-PET in imaging hepatocellular cancer, the limitations of this PET tracer and emerging novel PET tracers being investigated that exploit key metabolic processes including fatty acid and lipid synthesis, choline kinase activity and gene expression.

show abstract

Galectin‐4 serves as a prognostic biomarker for the early recurrence / metastasis of hepatocellular carcinoma

Cited by 53 publications

References 26 publications

Metastatic Progression of Prostate Cancer Is Mediated by Autonomous Binding of Galectin-4-O-Glycan to Cancer Cells

Metastatic Progression of Prostate Cancer Is Mediated by Autonomous Binding of Galectin-4-O-Glycan to Cancer Cells

Galectin 4 is a biomarker for early recurrence and death after surgical resection for pancreatic ductal adenocarcinoma

The emerging role of positron emission tomography in hepatocellular carcinoma

Contact Info

Product

Resources

About